Trans-inguinal pelvic lymphadenectomy in vulvar cancer patients: TRIPLE pilot study

Giorgia Garganese, Simona Maria Fragomeni, Luigi Della Corte, Carmine Conte, Benito Marinucci, Luca Tagliaferri, Stefano Gentileschi, Giacomo Corrado, Giuseppe Vizzielli, Giovanni Scambia

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Objective: The goal of this study was to assess the feasibility and safety of a retrograde extraperitoneal trans-inguinal novel approach to pelvic lymphadenectomy in vulvar cancer patients. The secondary objectives were to assess complications (early and late) and oncological outcomes. Methods: In this pilot study, all patients referred to our institution from November 2019 to May 2021 were evaluated. The inclusion criteria were patients diagnosed with primary/recurrent vulvar cancer and who were candidates for concomitant groin and pelvic lymph node dissection. A consecutive sampling was planned during the study period. After conventional inguino-femoral lymph nodal dissection, ipsilateral extraperitoneal trans-inguinal pelvic lymphadenectomy (TRIPLE) was performed through a groin incision. Clinical data, type of treatment, perioperative complications, and follow-up were evaluated. Results: 13 patients (8 primary, 5 recurrent vulvar cancer) underwent 16 TRIPLE procedures (10 unilateral, 3 bilateral). The median age was 69 years (range 58-93 years); 8 patients had comorbidities (61.5%). Up front locoregional radiotherapy was previously performed in two cases (15.4%). The pathology report showed metastatic lymph nodes in 20 (87%) groins and 11 (68.8%) pelvic sites; the mean number of removed and metastatic pelvic lymph nodes was 12.1 (range 5-33) and 2.9 (range 0-18), respectively. No intra-operative site-specific complications occurred. One (5.9%) post-operative site-specific complication was reported (pelvic abscess, grade 2), which was treated with antibiotics. One patient died due to concomitant pneumonia. No unilateral pelvic lymph node recurrence occurred during follow-up (median 13 months, range 2-43 months); 3 patients (23.1%) had distant site recurrence (median disease-free survival 9 months). Conclusions: TRIPLE seems to be a feasible and safe technique, providing adequate lymph node dissection. Despite being a high-risk and fragile population, morbidity was similar to previously reported data for conventional mini-invasive approaches. Prospective larger comparative series are necessary.
Lingua originaleEnglish
pagine (da-a)1-7
Numero di pagine7
RivistaInternational Journal of Gynecological Cancer
Stato di pubblicazionePubblicato - 2022


  • SLN and lympadenectomy
  • gynecologic surgical procedures
  • pelvis
  • surgical oncology
  • vulvar and vaginal cancer


Entra nei temi di ricerca di 'Trans-inguinal pelvic lymphadenectomy in vulvar cancer patients: TRIPLE pilot study'. Insieme formano una fingerprint unica.

Cita questo